Investigator uses ICTS resources for COVID-19 research and clinical trial efforts

Rachel M. Presti, MD, PhD
View Content

The CTSA program was developed to accelerate new treatments from the lab to patients, enabled to a large extent by patients participating in and benefiting from clinical trials. Clinical trials provide that needed bridge from human subjects to hypotheses to treatments that can directly benefit human health. And, never has this connection been more critical than amid the global COVID-19 pandemic.